The stock of Quintiles Transnational Holdings Inc (NYSE:Q) reached all time high today, Sep, 30 and still has $124.96 target or 54.00% above today’s $81.14 share price. This indicates more upside for the $9.60B company. This technical setup was reported by Barchart.com. If the $124.96 PT is reached, the company will be worth $5.18 billion more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 757,038 shares traded hands. Quintiles Transnational Holdings Inc (NYSE:Q) has risen 24.80% since February 26, 2016 and is uptrending. It has outperformed by 14.37% the S&P500.
Analysts await Quintiles Transnational Holdings Inc (NYSE:Q) to report earnings on October, 26. They expect $0.98 EPS, up 4.26% or $0.04 from last year’s $0.94 per share. Q’s profit will be $115.95M for 20.70 P/E if the $0.98 EPS becomes a reality. After $0.93 actual EPS reported by Quintiles Transnational Holdings Inc for the previous quarter, Wall Street now forecasts 5.38% EPS growth.
Quintiles Transnational Holdings Inc (NYSE:Q) Ratings Coverage
Out of 11 analysts covering Quintiles Transnational (NYSE:Q), 5 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 45% are positive. Quintiles Transnational has been the topic of 16 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The firm has “Market Perform” rating by Wells Fargo given on Thursday, May 12. The firm has “Outperform” rating by Credit Suisse given on Friday, August 14. Zacks downgraded the shares of Q in a report on Friday, September 4 to “Hold” rating. The stock of Quintiles Transnational Holdings Inc (NYSE:Q) has “Hold” rating given on Wednesday, May 4 by Evercore. As per Thursday, August 20, the company rating was upgraded by Zacks. The firm has “Buy” rating given on Tuesday, August 25 by Zacks. Deutsche Bank upgraded the stock to “Buy” rating in Friday, February 12 report. The rating was downgraded by SunTrust to “Neutral” on Monday, March 28. Argus Research maintained Quintiles Transnational Holdings Inc (NYSE:Q) on Thursday, July 30 with “Buy” rating. Zacks upgraded Quintiles Transnational Holdings Inc (NYSE:Q) on Thursday, August 27 to “Hold” rating.
According to Zacks Investment Research, “Quintiles Transnational Holdings Inc. provides professional services, information and partnering solutions to the pharmaceutical services, biotechnology and healthcare industries. The Company has two segments: Product Development and Integrated Healthcare Services. It offers project management, clinical monitoring services, strategic planning and design services, consulting services contract sales, market entry/market exit, integrated channel management, patient engagement, market access and commercialization consulting, brand and scientific communication, and medical education services; outcome/observational services. The Company operates in Americas, Europe and Africa, and the Asia-Pacific. Quintiles Transnational Holdings Inc. is based in Durham, North Carolina.”
Insitutional Activity: The institutional sentiment decreased to 1.13 in Q2 2016. Its down 0.22, from 1.35 in 2016Q1. The ratio worsened, as 39 funds sold all Quintiles Transnational Holdings Inc shares owned while 110 reduced positions. 54 funds bought stakes while 115 increased positions. They now own 108.59 million shares or 4.92% more from 103.49 million shares in 2016Q1.
Aperio Limited Liability holds 0.01% of its portfolio in Quintiles Transnational Holdings Inc (NYSE:Q) for 23,250 shares. Alliancebernstein L P has 0.24% invested in the company for 4.35M shares. Delta Lloyd Nv last reported 4,897 shares in the company. Wcm Management Ca holds 372,046 shares or 0.39% of its portfolio. Magnetar Fincl accumulated 0.01% or 8,452 shares. Capstone Asset last reported 0.01% of its portfolio in the stock. Cantab Partners Llp last reported 15,889 shares in the company. Copper Rock Llc accumulated 0.02% or 3,275 shares. Connor Clark & Lunn Invest Management owns 82,700 shares or 0.04% of their US portfolio. Royal Bank & Trust Of Canada has invested 0% of its portfolio in Quintiles Transnational Holdings Inc (NYSE:Q). The Massachusetts-based Adage Partners Grp Incorporated Lc has invested 0.05% in Quintiles Transnational Holdings Inc (NYSE:Q). Moreover, Wellington Management Gru Limited Liability Partnership has 0.05% invested in Quintiles Transnational Holdings Inc (NYSE:Q) for 2.95M shares. Reinhart Prtnrs Incorporated accumulated 186,963 shares or 1.22% of the stock. Envestnet Asset accumulated 0.02% or 66,821 shares. Evercore Wealth Management Ltd Liability Com has invested 0% of its portfolio in Quintiles Transnational Holdings Inc (NYSE:Q).
More notable recent Quintiles Transnational Holdings Inc (NYSE:Q) news were published by: Seekingalpha.com which released: “Quintiles Transnational: A Total Return Growth Biopharmaceutical (Part 7 …” on September 26, 2016, also Bloomberg.com with their article: “IMS Health to Buy Quintiles in $9 Billion Pharma Data Deal” published on May 03, 2016, Forbes.com published: “Quintiles Transnational Holdings Enters Oversold Territory (Q)” on June 17, 2016. More interesting news about Quintiles Transnational Holdings Inc (NYSE:Q) were released by: Businesswire.com and their article: “Annie Hai-yuan Lo Elected to Quintiles Transnational Holdings Inc. Board of …” published on September 28, 2015 as well as Economictimes.Indiatimes.com‘s news article titled: “IMS Health-Quintiles Transnational deal gets Competition Commission nod” with publication date: August 24, 2016.
Q Company Profile
Quintiles Transnational Holdings Inc., incorporated on November 19, 2009, is a well-known provider of biopharmaceutical development services and commercial outsourcing services. The Firm is engaged in the development and commercialization of pharmaceutical therapies. The Company’s divisions include Product Development and Integrated Healthcare Services. The Firm offers therapeutic, scientific and analytics services to its biopharmaceutical and other healthcare customers. The Company’s Product Development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. The Company’s Integrated Healthcare Services segment includes commercial pharmaceutical sales and service organizations. The Company’s Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services for the healthcare sector, such as phase research, market access and consulting, health information analytics and technology consulting, and other healthcare solutions.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.